Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 4, 2021

Coronavirus company news summary – BARDA and LightDeck partner to develop rapid SARS-CoV-2 antigen test – FDA approves UI’s coronavirus test

By Chloe Kent

The Biomedical Advanced Research and Development Authority (BARDA) and LightDeck Diagnostics have partnered to create a six-minute SARS-CoV-2 antigen test, which can be used without a diagnostic laboratory. The point-of-care test can be used for on-site screening of Covid-19 at non-clinical settings, nursing homes, community testing sites, and essential workplaces.

University of Illinois researchers have obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a saliva-based Covid-19 test.  The 99% accurate saliva-based test is expanded to all nine other public university campuses and to 48 community colleges. Approximately $20m in federal funds is expected to enable one million Covid-19 tests for Illinois colleges.

Related Companies

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy